1 of 4
Rising nicotine pouch demand is driving a shift toward local production. Photo credit: PMI US.
2 of 4
PMI US opens US$1.2 billion Aurora campus, strengthening US manufacturing and export capabilities. Photo credit: PMI US
3 of 4
Inside PMI’s largest nicotine pouch manufacturing facility. Photo credit: PMI US.
4 of 4
Imperial Brands centralizes Zone pouch production in Lithuania to supply European markets. Photo credit: Alexclere CC4.0
How automation, regulation, and global investment are reshaping where the world’s nicotine pouches are produced.
Nothing about the shift was sudden. For a long time, nicotine pouches were a small Scandinavian niche category, primarily for nearby consumers seeking to quit combustible cigarettes, moist snuff, and other traditional oral tobacco products.
The story has changed dramatically. Nicotine pouches have become one of the sector’s biggest magnets for capital growth, and that capital is driving a familiar set of moves: new plants, increased automation, tighter supply arrangements, and a push to bring production closer to the fastest-growing markets.
From North America to Europe to parts of Asia, billions are being spent on factories and equipment, and companies are reevaluating basic decisions about where to make these pouches and what the real advantage is. Some firms are choosing to manufacture closer to their largest customer bases, while others are building regional export platforms.
Contract manufacturers are scaling up as multinational tobacco groups expand. Look at the announcements together, and it’s more than a burst of construction news. They reveal the outlines of a new manufacturing category taking shape.
Cigarettes followed one pattern for decades. Nicotine pouches are following another. While cigarette production historically tracked tobacco-growing regions and legacy infrastructure, pouch manufacturing is settling into a different industrial logic. New sites increasingly resemble advanced food and pharmaceutical operations: quality systems built to satisfy regulators, not merely to move volume.
Tobacco remains a source material for nicotine extraction. Even so, day-to-day manufacturing priorities are shifting toward technology, repeatability, and compliance. In an increasing share of “white pouch” products, synthetic nicotine changes the equation again by eliminating the need for traditional tobacco leaf.
As inputs and methods evolve, the global footprint shifts accordingly. Philip Morris International is investing an estimated US$1.2 billion in its Aurora, CO, campus, scaling up a US$600 million plan to build its largest nicotine pouch manufacturing facility and one of the largest smoke-free business bets in North America. Commercial production began in 2025. Buildout and additional capacity are scheduled to continue through 2028, as more production lines and supporting infrastructure come online.
Swisher International, the producer of Rogue tobacco-free nicotine pouches and Mojo caffeine and energy pouches, pledged US$135 million to expand its Jacksonville, FL, complex as it further expands into nicotine pouches and the broader modern oral lineup. Turning Point Brands expects domestic production of its nicotine pouch brands to begin by year-end.
Independent players are also moving, including Fully Loaded, which is investing in dedicated US manufacturing to support long-term growth. Outside the US, Imperial Brands is positioning Lithuania as a production base for Zone across Europe. Bangladesh has approved what is expected to be the country’s first nicotine pouch manufacturing operation.
Chinese companies continue to expand their role as suppliers, not so much of finished pouches as of the machinery, production know-how, and engineering support that nicotine companies worldwide are buying. On their own, each update reads like another factory-opening story. Side by side, they look like a map being redrawn as everyone watches. “The manufacturing conversation has changed,” said Waqas Khan, c.e.o. of CLEW Pouches. “Companies aren’t simply looking for someone who can produce a pouch anymore. They’re looking for partners who can scale production, maintain consistency, meet regulatory expectations and grow with them as their brands expand.” That’s a larger shift than it first sounds. Manufacturing is no longer treated as a background requirement to be solved and then forgotten. It’s increasingly a source of competitive advantage: lowering unit costs, improving consistency, shortening supply chains, and accelerating expansion.
Boardrooms are discussing it on exactly those terms. “We continue to invest in manufacturing capacity, commercialization, and innovation because we remain confident in the long-term opportunity for smoke-free products,” said Philip Morris International c.e.o. Jacek Olczak, addressing continued investment in Zyn.
Turning Point Brands has been making a similar case. “We remain on track to launch US manufacturing by the end of the year,” president and c.e.o. Graham Purdy said on an earnings call, adding that domestic production should reduce manufacturing costs and support long-term growth.
Turning Point Brands’ c.f.o. Andrew Flynn tied the timing to regulation. “We’re just being mindful of the process and dedicating ourselves to the US Food and Drug Administration’s premarket tobacco product application process (PMTA) first and foremost,” Flynn said. “As we get positive visibility there, we’ll be able to move quickly.”
The point is hard to miss. It’s not only about where labor is cheapest. Factories aren’t being planned solely because of demand. They’re being designed around automation, logistics, the likelihood of regulatory clarity, and a multi-year commercial plan.
More than another factory
A modern nicotine pouch factory doesn’t look much like the cigarette factories that defined tobacco manufacturing for most of the 20th century. Cigarettes were built around leaf. Raw tobacco moved through threshing, blending, and conditioning, then through cigarette production and packaging, before entering supply chains refined over decades.
Location choices often came down to proximity to tobacco production or to established industrial corridors. Pouches have changed the rules. Because pharmaceutical-grade nicotine can be extracted from tobacco or made synthetically and shipped without the rest of the leaf processing, manufacturers aren’t as directly tied to tobacco farmland as cigarette producers were.
The facilities currently under construction are designed to support automation, export logistics, quality assurance, and scalability. That shift raises expectations across the board. Brand owners want precise dosing, consistent pouch weights, stable flavor profiles, and repeatable moisture control across millions of units.
Inspection systems now monitor quality at speeds no manual process can match. Packaging lines are becoming as much about traceability as about speed, as tracking requirements are increasingly embedded in regulatory systems worldwide. For contract manufacturers, that evolution shifts the entire sales pitch.
“It’s about capabilities,” Khan said. “Can they support your growth? Can they maintain quality from one production run to the next? Can they protect your formulations and intellectual property? Can they adapt as regulations change? Those questions are becoming much more important than simply asking who can manufacture at the lowest cost.”
Labor cost still matters, but it is less of a differentiator. More often, competition centers on engineering depth, equipment, quality systems, and the ability to scale alongside customers. That difference may ultimately determine where the next generation of factories is located.
Thomas Agaraté, c.e.o. of Outdare LLC and founder of DarePouch, a Europe-based online pouch marketplace, said he vetted an estimated 15 potential OEM manufacturing partners across Europe and Asia for his house pouch brand. What settled the decision wasn’t a pitch, he said; it was two things you can literally test.
“First, whether they would develop a flavor with us rather than sell us one out of a catalog. We spent about six months iterating on a single mint before we’d sign off, and we replaced most of the sucralose with xylitol along the way. Plenty of suppliers won’t do that at our volume,” explained Agaraté. “Second, whether they’d let us hold one spec across three different actives. OutDare offers nicotine, caffeine, and CBD products, and the whole point is that they feel the same in the lip—same moisture, same burn intensity. We specify that burn as a fixed level, and it is identical across all three products.”
Agaraté insists that contract manufacturing is a win for almost everyone, especially small- and mid-sized companies. He said that owning your own production makes sense only at volumes very few brands reach, and the barrier isn’t know-how—it’s capital, plus the regulatory burden of being the manufacturer of record in every market you sell into.
“The brands that do build will do so to protect a formulation they can’t afford to have copied or to secure supply after being burned by someone else’s capacity, not to save money. That math rarely works,” he said. “For our part: no plans to build. We’d rather spend on range and availability.”
Following the consumer
For most of the tobacco industry’s history, manufacturing decisions were tied to agriculture. Production facilities clustered near tobacco-growing regions because hauling large volumes of cured leaf across oceans and continents was and remains costly and inefficient. The basic formula was simple: get close to the raw material, process it, make the finished product, and ship it.
Today, placement is increasingly driven by consumer demand, logistics, regulatory predictability, and operational efficiency rather than proximity to a farm or tobacco auction market. “The conversation has shifted from where tobacco grows to where consumers are,” Khan said. “Today’s manufacturing decisions are driven by market access, quality systems, and scalability. Those are the factors brand owners ask about first.”
No market illustrates that change more clearly than the United States. Nicotine pouch demand has risen quickly in recent years, prompting companies to shift to local production rather than relying primarily on imports from Europe. PMI’s Aurora expansion aligns with that approach. It’s intended to become PMI’s largest pouch site, shorten the supply chain, improve responsiveness, and place production near one of the world’s fastest-growing nicotine pouch markets.
Smaller companies are moving in the same direction. Turning Point Brands is preparing to launch domestic manufacturing after building its FRĒ and ALP brands largely through outsourced production. “We remain on track to launch US manufacturing by the end of the year,” Purdy said. The investment isn’t only about increasing output. “Over time, we expect domestic manufacturing to significantly reduce our cost of goods sold,” Purdy told analysts, adding that the facility could eventually support gross margins approaching 70%.
Another pattern emerges alongside these plans: regulation. Companies are weighing locations not only for labor pools or incentives but also for how efficiently a site can comply with evolving rules, support market authorization, and adapt to market changes. FDA’s nicotine pouch pilot program, which has increased the number of authorized products and shortened review time-lines, has given firms greater confidence that domestic production investments can be supported by clearer pathways to market.
Europe tends to operate differently. Rather than building separate plants for each country, companies are relying on centralized hubs to supply multiple markets simultaneously. Imperial Brands has taken that approach with its nicotine pouch brand Zone, using Lithuania to serve growing European demand while keeping quality control and distribution centralized.
That idea is now emerging in other regions as well. The Bangladesh operation is giving Philip Morris Bangladesh a domestic base that could evolve into a platform for local sales and regional exports. Similar concepts are under consideration across Asia and the Middle East as manufacturers seek production footholds closer to emerging demand. These shifts are also reshaping expectations for what contract manufacturers should provide.
Instead of competing primarily on price, more companies are distinguishing themselves through automation, formulation expertise, research and development capabilities, and regulatory support. “Manufacturing relationships have become long-term partnerships,” Khan said. “Companies want to know their manufacturer can support product development, regulatory requirements, new markets, and future growth. That’s a very different discussion than it was just a few years ago.”
Factories, in other words, are becoming strategic assets. They influence how quickly a company can enter new markets, respond to new regulations, and scale its operations.
The next production race
If the last decade was about proving that consumers wanted smoke-free oral nicotine, the next decade might be shaped by something less visible: the factories. The capacity race isn’t only about meeting demand. Automation is central to the transition. People remain essential, but the focus shifts. Rather than manual production tasks, more time is devoted to engineering, quality assurance, process improvement, and compliance.
“Consistency is everything,” Khan said. “Consumers expect the same experience every time they open a can, regardless of where it was produced. That requires investment in equipment, quality systems and manufacturing expertise.” That spending has changed the economics. A modern nicotine pouch factory requires more than buying lines and turning them on. Quality systems must be built and maintained. Processes must be validated. Ingredient suppliers must be reliable. Regulatory expectations are becoming more detailed.
Facilities must also leave room for innovation as product formats and formulations continue to evolve. For many newer brands, those realities keep contract manufacturing the simplest route. “The exception is when a company reaches sufficient scale or has strategic reasons to control production,” Khan said. “Until then, working with an experienced manufacturing partner often allows a brand to focus on product development, commercialization, and consumer growth while still benefiting from world-class production.”
At the same time, large tobacco groups continue to expand vertically. PMI’s Aurora campus, Swisher’s Florida buildout, Turning Point Brands’ planned US production, and Imperial Brands’ European strategy all reflect the same calculation: owning production can strengthen supply chains, improve efficiency, and confer advantages beyond a lower unit cost.
China, for its part, is strengthening its position as a supplier of manufacturing technology, engineering expertise, and production equipment to nicotine companies worldwide. As more countries establish regulatory pathways, the network is likely to expand further. Some places will become production hubs, others may focus on research and development, and some will emerge as contract manufacturing centers, producing for dozens of brands that never build their own factories. One thread runs through all of it: manufacturing has moved to the center of strategy. FDA’s nicotine pouch pilot program has already shown that regulatory efficiency can guide commercial investment. Similar shifts abroad are giving companies greater confidence to commit long-term capital to new sites.
Tomorrow’s market-leading nicotine pouch brands may be determined not only by who builds the strongest market presence but also by who builds the smartest manufacturing facilities. Consumers won’t see the automated lines, labs, or engineering systems behind their favorite nicotine pouch. Still, decisions made inside these facilities, from Colorado and Florida to Lithuania, Bangladesh, and beyond, are quietly reshaping one of the fastest-growing segments of the global nicotine industry. The next chapter in nicotine pouches won’t be written on store shelves. It will be written on the factory floor.